BioLife Solutions has announced the completion of construction and validation of its internal GMP manufacturing facility. The company has released first production lot of its biopreservation media products
Raptor has announced that it has signed a collaboration and licensing agreement with Roche to evaluate therapeutic delivery across the blood-brain barrier (BBB), starting with Raptor’s proprietary NeuroTrans
Roche has announced that it will start phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality
“Today’s announcement marks another milestone in the successful partnership between ICON and Lilly,” commented Peter Gray, CEO at ICON. “We have worked together to create a truly flexible
Bioniche and Synerx have announced the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran from GlaxoSmithKline. Bioniche and Synerx entered into an
CEL-SCI has announced that it is expanding the pre-clinical testing of its flu vaccine, utilizing its proprietary LEAPS technology (Ligand Epitope Antigen Presentation System). The testing is intended
MDS Pharma has announced that renovation and expansion of its discovery pharmacology operation in Taiwan is under way, to serve the growing global demand for work performed in
DOR has announced that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase-III clinical trial. The trial
United Therapeutics and Eli Lilly have announced the results of a pivotal 16-week study. The results showed that once-daily dose of tadalafil was generally well tolerated, improved exercise
D-Pharm announced that it has received FDA approval for its Investigational New Drug (IND) application for a pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.